Clearmind Historical Financial Ratios
| CMND Stock | USD 1.38 0.01 0.73% |
Clearmind Medicine is presently reporting on over 89 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.8 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Clearmind Medicine Common financial condition quickly.
Clearmind |
About Clearmind Financial Ratios Analysis
Clearmind Medicine CommonFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Clearmind Medicine investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Clearmind financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Clearmind Medicine history.
Clearmind Medicine Financial Ratios Chart
Add Fundamental
Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Clearmind Medicine Common. There are two different methods for calculating Clearmind Medicine Common invested capital: operating approach and financing approach. Understanding Clearmind Medicine invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Clearmind Medicine's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Clearmind Medicine Common current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Clearmind Medicine's Average Payables is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 1.80, whereas Free Cash Flow Yield is forecasted to decline to (0.99).
| 2022 | 2023 | 2024 | 2025 (projected) | Net Debt To EBITDA | 0.62 | 1.11 | 1.28 | 1.22 | Intangibles To Total Assets | 0.02 | 0.0149 | 0.0172 | 0.0163 |
Clearmind Medicine fundamentals Correlations
Click cells to compare fundamentals
Clearmind Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Clearmind Medicine fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 0.0454 | (3.09) | 5.42 | 1.91 | 1.72 | 1.8 | |
| Book Value Per Share | 15.53 | (3.48) | 0.49 | 0.73 | 0.84 | 0.8 | |
| Free Cash Flow Yield | (14.07) | (1.09) | (0.85) | (0.82) | (0.94) | (0.99) | |
| Operating Cash Flow Per Share | (9.17) | (11.73) | (3.12) | (1.14) | (1.31) | (1.38) | |
| Pb Ratio | 0.0454 | (3.09) | 5.42 | 1.91 | 1.72 | 1.8 | |
| Free Cash Flow Per Share | (9.92) | (11.75) | (3.12) | (1.14) | (1.31) | (1.38) | |
| Roic | (0.76) | 5.78 | (8.91) | (2.15) | (2.47) | (2.35) | |
| Net Income Per Share | (13.34) | (21.72) | (5.92) | (1.23) | (1.42) | (1.49) | |
| Cash Per Share | 14.88 | 1.02 | 2.72 | 1.61 | 1.45 | 2.36 | |
| Pocfratio | (0.0769) | (0.92) | (1.17) | (1.22) | (1.1) | (1.15) | |
| Capex To Operating Cash Flow | (0.16) | (0.0378) | (0.0815) | (0.001494) | (0.001344) | (0.001411) | |
| Pfcf Ratio | (0.0711) | (0.92) | (1.17) | (1.22) | (1.1) | (1.15) | |
| Roe | (0.86) | 6.23 | (8.77) | (1.69) | (1.94) | (2.04) | |
| Ev To Operating Cash Flow | 0.61 | 1.55 | (0.89) | (0.31) | 0.12 | 0.11 | |
| Pe Ratio | (0.0529) | (0.5) | (0.62) | (1.13) | (1.02) | (1.07) | |
| Return On Tangible Assets | (0.83) | (9.9) | (2.05) | (0.74) | (0.85) | (0.89) | |
| Ev To Free Cash Flow | 0.59 | 1.43 | (0.89) | (0.31) | 0.12 | 0.11 | |
| Earnings Yield | (18.91) | (2.02) | (1.62) | (0.89) | (1.02) | (1.07) | |
| Net Debt To E B I T D A | 1.25 | 0.0145 | 0.62 | 1.11 | 1.28 | 1.22 | |
| Current Ratio | 13.78 | 0.22 | 1.17 | 1.72 | 1.97 | 1.87 | |
| Tangible Book Value Per Share | 14.89 | (3.89) | 0.43 | 0.7 | 0.81 | 0.77 | |
| Graham Number | 68.28 | 41.26 | 9.48 | 4.49 | 4.04 | 3.84 | |
| Shareholders Equity Per Share | 15.53 | (3.48) | 0.68 | 0.73 | 0.84 | 0.8 | |
| Capex Per Share | 0.0811 | 0.0552 | 0.75 | 0.0175 | 0.0202 | 0.0191 | |
| Graham Net Net | 1.74 | 14.04 | (5.07) | 0.34 | 0.77 | 0.73 | |
| Enterprise Value Over E B I T D A | 1.19 | (0.54) | (0.23) | 0.1 | 0.091 | 0.0956 | |
| Price Earnings Ratio | (0.0529) | (0.5) | (0.62) | (1.13) | (1.02) | (1.07) | |
| Price Book Value Ratio | 0.0454 | (3.09) | 5.42 | 1.91 | 1.72 | 1.8 | |
| Price Earnings To Growth Ratio | (5.9E-5) | (0.006501) | 0.008273 | 0.0118 | 0.0106 | 0.0111 | |
| Price To Operating Cash Flows Ratio | (0.0769) | (0.92) | (1.17) | (1.22) | (1.1) | (1.15) | |
| Price To Free Cash Flows Ratio | (0.0711) | (0.92) | (1.17) | (1.22) | (1.1) | (1.15) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.